Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels

References

• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008;112:1557–1569.
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol 2015;15:57–65.
   PubMed Web of Science ®Google Scholar
• Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med 2015;373:1241–1249.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma: Global strategy for asthma management and prevention (updated 2015). Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_May19.pdf. [last accessed 16 April 2016].
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2015). Available from: http://www.goldcopd.org/uploads/users/files/WatermarkedGlobal%20Strategy%202016(1).pdf [last accessed 16 April 2016]
   Google Scholar
• Sakuishi K, Oki S, Araki M, et al. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 2007;179:3452–3462.
   PubMed Web of Science ®Google Scholar
• Rabih H, Al-Kufaidy R, Vazquez-Tello A, et al. IL-17 Enhances chemotaxis of primary human B cells during asthma. PLoS One 2014;9:e114604.
   PubMed Web of Science ®Google Scholar
• Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430–438.
   PubMed Web of Science ®Google Scholar
• McKinley L, Alcorn JF, Peterson A, et al. Th17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008;181:4089–4097.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716–725.
   PubMed Web of Science ®Google Scholar
• Snider GL. Chronic obstructive pulmonary disease--a continuing challenge. Am Rev Respir Dis 1986;133:942–944.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hogg JC. Convergence of the epidemiology and pathology of COPD. Thorax 2006;61:86–88.
   PubMed Web of Science ®Google Scholar
• Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114–1121.
   PubMed Web of Science ®Google Scholar
• Doe C, Bafadhel M, Siddiqui S, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010;138:1140–1147.
   PubMed Web of Science ®Google Scholar
• Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;191:758–766.
   PubMed Web of Science ®Google Scholar
• Yalcin AD. Advances in anti-IgE therapy. Bio Med Res Int 2015;11:317465.
   Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157–162.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Gorczynski RM, Parlak GE, et al. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab 2012;58:89–96.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A, Kargi A, Gorczynski RM. Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Med Sci Monit 2012;18:11–15.
   Web of Science ®Google Scholar
• Yalcin AD, Gumuslu S, Parlak GE, et al. Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis. Immunopharmacol Immunotoxicol 2012;34:1047–1053.
   PubMed Web of Science ®Google Scholar
• Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003;111:256–262.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A. The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab. Med Sci Monit 2012;18:LE9–LE10.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A. Omalizumab: anti-IgE therapy in severe allergic conditions. Aller Ther J 2011;3:120. doi: 10.4172/2155-6121.1000120.
   Google Scholar
• John M, Lim S, Seybold J, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1α, granulocyte-macrophage colony-stimulating factor, and interferon-γ release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998;157:256–262.
   PubMed Web of Science ®Google Scholar
• Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011;38:1019–1028.
   PubMed Web of Science ®Google Scholar
• Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis 2010;73:86–87.
   PubMedGoogle Scholar
• Zeidel A, Beilin B, Yardeni I, et al. Immune response in asymptomatic smokers. Acta Anaesthesiol Scand 2002;46:959–964.
   PubMed Web of Science ®Google Scholar
• Hollander C, Sitkauskiene B, Sakalauskas R, et al. Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir Med 2007;101:1947–1953.
   PubMed Web of Science ®Google Scholar
• Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334–1356.
   PubMed Web of Science ®Google Scholar
• Caramori G, Di Stefano A, Casolari P, et al. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease. Curr Med Chem 2013;20:4317–4349.
   PubMed Web of Science ®Google Scholar
• Shukla M, Kumar P, Mishra V, et al. Carryover of cigarette smoke effects on hematopoietic cytokines to F1 mouse litters. Mol Immunol 2011;48:1809–1817.
   PubMed Web of Science ®Google Scholar
• van der Deen M, Timens W, Timmer-Bosscha H, et al. Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice. Respir Res 2007;8:49.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012;83:36–44.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114–120.
   PubMed Web of Science ®Google Scholar
• Kersul AL, Iglesias A, Ríos A, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011;47:176–183.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012;2012:720976.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926–934.
   PubMed Web of Science ®Google Scholar
• Liang Q, Guo L, Gogate S, et al. IL-2 and IL-4 Stimulate MEK1 expression and contribute to T cell resistance against suppression by TGF-beta and IL-10 in asthma. J Immunol 2010;185:5704–5713.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang S MD, Erekosima N, et al. IL-4 confers resistance to IL-27-mediated suppression on CD4+ T cells by impairing signal transducer and activator of transcription 1 signaling. J Allergy Clin Immunol 2013;132:912–921.e5.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Celik B, Gumuslu S. D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment. Expert Opin Biol Ther 2014;14:283–286.
   PubMed Web of Science ®Google Scholar
• Ozge A, Ozge C, Kaleagasi H, et al. Headache in patients with chronic obstructive pulmonary disease: effects of chronic hypoxaemia. J Headache Pain 2006;7:37–43.
   PubMedGoogle Scholar